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Abstract A growing body of experimental evidence indicates that immune cells
move in an unrestricted search pattern if they are in the pre-activated state, while
they tend to stay within a more restricted area upon activation induced by the
presence of tumour antigens. This change in movement is not often considered in
the existing mathematical models of the interactions between immune cells and
cancer cells. With the aim to fill such a gap in the existing literature, in this
work we present a spatially structured individual-based model of tumour-immune
competition that takes explicitly into account the difference in movement between
inactive and activated immune cells. In our model, a Le´vy walk is used to capture
the movement of inactive immune cells, whereas Brownian motion is used to de-
scribe the movement of antigen-activated immune cells. The effects of activation
of immune cells, the proliferation of cancer cells and the immune destruction of
cancer cells are also modelled. We illustrate the ability of our model to reproduce
qualitatively the spatial trajectories of immune cells observed in experimental data
of single cell tracking. Computational simulations of our model further clarify the
conditions for the onset of a successful immune action against cancer cells and
suggest possible targets to improve the efficacy of cancer immunotherapy. Over-
all, our theoretical work highlights the importance of taking into account spatial
interactions when modelling the immune response to cancer cells.
Keywords Cancer-Immune Competition · Spatial Movement · Individual-Based
Models · Le´vy Walk · Brownian Motion
1 Introduction
Recent advances in technology have allowed for a deeper understanding of the
individual interactions occurring between cancer cells and cells of the human im-
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mune system, and how these could be exploited using immunotherapies (Basu
et al, 2016; Boissonnas et al, 2007; Engelhardt et al, 2012; Halle et al, 2016; Pitt
et al, 2016; Tan et al, 2015).
The immune system is made up of two parts: the innate response and the
adaptive immune response. Cells of the innate immune response, such as natural
killer (NK) cells, can cause limited damage to a solid tumour resulting in tumour
cell debris in the microenvironment. This debris contains tumour antigens (i.e.
smaller proteins produced by the tumour) which can be ingested by nearby innate
dendritic cells (DCs) (Messerschmidt et al, 2016). The DCs can then activate
adaptive cytotoxic T lymphocytes (CTLs) through antigen presentation, which is
a key step in determining whether the immune system will be capable of removing
a tumour (Boissonnas et al, 2007; Engelhardt et al, 2012). Once the activated
CTLs have reached the site of the cancer cells, they can cause cancer cell death
via apoptosis through direct interaction or release of chemicals (Hersey and Zhang,
2001; Modiano and Bellgrau, 2016).
Immunotherapies based on T lymphocytes have been widely researched re-
cently, with the aim to enhance the response of T lymphocytes to solid tumours
(Andersen et al, 2016; Frigault and Maus, 2016; Gross and Eshhar, 2016; Ikeda,
2016). Adoptive T cell therapies rely on T lymphocytes from the patient, or from
donor patients, to be modified and then (re)injected into the patient. The lym-
phocytes are removed from the body and then undergo incubation with cytokines
to allow for expansion ex vivo. They are then transferred back into the patient
with the aim that they are able to specifically target cancer cells (Gross and Es-
hhar, 2016). In a similar method dendritic cells can be removed from the body
and expanded or activated using tumour antigens ex vivo, promoting an enhanced
response of T lymphocytes once reinjected into the patient (Carreno et al, 2015;
Prue et al, 2015; Schreibelt et al, 2016; Tel et al, 2013; Weinberg, 2007a; Wilgenhof
et al, 2016, 2011).
The use of mathematical modelling to capture the interactions between the
immune system and cancer has been widely examined over the past few decades.
The majority of the models use ordinary differential equations (ODEs) or integro-
differential equations (IDEs) to describe cellular level dynamics, with many of them
focusing on tumour cells interacting with cytotoxic T lymphocytes (Bellomo and
Delitala, 2008; Bunimovich-Mendrazitsky et al, 2008; Cattani et al, 2010; Delitala
and Lorenzi, 2013; Frascoli et al, 2014; Kolev, 2003; Kuznetsov and Knott, 2001;
Kuznetsov et al, 1994; Lin Erickson et al, 2009; Lorenzi et al, 2015; Takayanagi
and Ohuchi, 2001; Wilkie and Hahnfeldt, 2013). From these non-spatial models
the effect of immune evasion by the cancer cells has been well described, with
the parameter values of the models being derived either from experimental data
or estimated logically. Key dynamics can be confirmed or expanded in a wider
range of biologically relevant situations by developing these ODE and IDE models
into partial differential equation (PDE) models through the inclusion of spatial
movement (e.g. random motility, chemotaxis) of the cells (Al-Tameemi et al, 2012;
d’Onofrio and Ciancio, 2011; Matzavinos et al, 2004). Models of this type allow
for a deeper understanding of the immune evasion processes and have highlighted
situations of cancer dormancy, where a small tumour continues to exist but is
maintained at a restricted size by the immune system. They can also shed light on
immunotherapies and cancer vaccination protocols (Joshi et al, 2009). Differential
equation models are useful and, in addition to providing insight through simu-
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lation, are amenable to mathematical analysis to achieve conclusions concerning
structural stability under parameter changes. However, the differential formalism
poses some limitation to the level of biological detail which can be incorporated
in these models. By using computational models such as cellular automata (CA)
and individual-based models (IBMs) a wider spectrum of biological phenomena
can be translated into mathematical terms and described. These models can be
posed on a spatial domain (e.g. a grid), and a set of rules can be given to each
cell with certain probabilities to achieve a more detailed description of cancer-
immune competition (Chowdhury et al, 1991; Christophe et al, 2015; Hu et al,
2012; Pappalardo et al, 2008).
Advances in imaging techniques have allowed individual cell tracking to be-
come a reality, and through this a key aspect of immune cell motion has been
discovered, i.e. CTLs move in an unrestricted search pattern if they are in the
pre-activated state. This allows them to move larger distances more quickly. How-
ever, once activated via presentation of a tumour antigen, CTLs adopt a more
restricted movement, allowing them to stay within a confined area (Boissonnas
et al, 2007). DCs have been shown to have similar properties and their movement
becomes restricted after obtaining a tumour antigen (Engelhardt et al, 2012).
This change in the type of movement is not often considered in the existing math-
ematical models of the interactions between immune cells and cancer cells. With
the aim to fill such a gap in the existing literature, in this paper we present a
spatially structured individual-based model of tumour-immune competition that
explicitly takes into account the difference in movement between inactive and ac-
tivated immune cells. In our model, a Le´vy walk is used to model the movement of
inactivated immune cells, whereas Brownian motion is used to describe the move-
ment of antigen-activated immune cells. Additionally, the effects of activation of
immune cells, proliferation of cancer cells and immune destruction of tumour cells
are incorporated in the model.
The remainder of the paper is organised as follows. In Section 2, we outline the
mathematical model and describe how we parametrise the model using data from
the existing literature. In Section 3, we present the main computational results
that we obtain varying the model parameters to consider a number of biological
scenarios. Finally, in Section 4 we discuss the implications of these results and
present directions for future work.
2 The mathematical model
In our model three cell types are considered: cancer cells (from a solid tumour),
dendritic cells and cytotoxic T lymphocytes. The total numbers of these cells
will be denoted by NT , ND and NC , respectively. We describe the interactions
occurring between the three cell types in an in vitro situation using an individual-
based modelling approach.
Our IBM is posed on a 2D spatial grid of spacing ∆x in the x direction and
∆y in the y direction, with the constraint that only one cell of any type is allowed
at each grid-site at any time-step of duration ∆t.
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Fig. 1 Mechanisms and processes included in the model. Three different cell types
and five different cell states are considered in the model (Key subpanel). (a) Tumour cells can
proliferate if a neighbouring position is free at rate λ. (b) Dendritic cells (DCs) can become
activated by uptake of antigen from the tumour upon contact at rate DAct. (c) Activated DCs
can present the antigen to inactive cytotoxic T lymphocytes (CTLs) upon contact allowing
them to become activated at rate CAct. (d) Activated CTLs can remove tumour cells upon
contact at rate µ
2.1 Proliferation of tumour cells
We allow the (solid) tumour to grow through cancer cell proliferation. A cancer
cell divides at rate λ into two daughter cells of which one occupies the position
of the mother cell while the other is positioned at an unoccupied neighbouring
grid-site, Fig.1a. This ensures that only cancer cells with free grid-sites in their
neighbourhood can proliferate.
In early stages of tumourigenesis, cancer cells must stay close to the original
site of the tumour (Hanahan and Weinberg, 2011). Once the tumour has developed
and is large enough, single cells can leave the tumour mass and travel to other
sites of the body (Weinberg, 2007b). In our model, we consider a case where the
tumour is at an early stage of its development and not significantly large enough to
initiate this process (invasion and metastasis), and so we do not consider cancer
cell movement. Moreover, self-induced cell death of the cancer cells is omitted
from the model, a factor which can be explained by telomeric shortening. In fact,
the process that leads human cells to induce their own cell death depends on
the telomeres at the end of chromosomes shortening. Once the telomeres shorten
significantly the cell can no longer replicate and will initiate apoptosis. Most cancer
cells express high levels of telomerase, an enzyme that prevents the telomeres
shortening allowing for infinite survival of cells (Shay et al, 2001).
2.2 Movement of inactive immune cells
We assume that initially both types of immune cells, CTLs and DCs, are in an
inactive state and randomly distributed throughout the domain. Boissonnas et al
(2007) used individual cell tracking to study the movement of CTLs in the presence
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Fig. 2 Cell neighbourhood and mechanisms of immune cell motion. (a) At each
time-step, immune cells can move to one of the eight neighbouring grid-sites provided it is
unoccupied. (b) Inactive immune cells move via a Le´vy walk and the probability of moving
in a given direction for s time-steps is taken from the Le´vy distribution given by Eq.(1).
(c) Activated immune cells move via Brownian motion and the probability of moving to
neighbouring grid-sites is the same at each time-step
and absence of a tumour antigen, and verified a change in the type of movement
between these situations. In the case where no antigen was present, the cells moved
actively in a search like pattern. On the other hand, when the tumour antigen was
present, the cells switched to a form of movement that leads them to cover a
more restricted portion of space during the same time interval. This corresponds
to situations where the immune cells will either be inactive or activated by the
tumour antigen. Engelhardt et al (2012) discovered similar results when studying
the movement of dendritic cells in response to a solid tumour, where the change in
movement was linked to antigen activation. In order to incorporate this into our
model, we choose two forms of random walk to describe immune cell movement:
we let inactive cells move via a Le´vy walk mechanism and activated cells move via
Brownian motion. At each time-step, cells move to an unoccupied neighbouring
grid-site, Fig.2a. If a cell is using a Le´vy walk, the direction of movement is initially
chosen randomly (i.e. with equal probability) from one of the eight directions
shown in Fig.2a. Then the number of time steps s that the cell persists in this
direction is chosen from the Le´vy distribution given by Eq.(1). If the number of
steps is one (i.e. s = 1), then the process repeats at the next time-step, otherwise
the cell will keep moving in the initially chosen direction until all steps have been
taken. Once the step-number is zero, the process begins again. The mechanism
follows the rule that cells cannot move to an occupied grid-site or a grid-site
outside the boundary of the domain. The Le´vy distribution is defined as
P(s) = s−(α+1), (1)
where s is the number of time-steps the cell will move in a given direction and α is
the walk exponent (see Harris et al (2012) for full details). This means that cells
whose motion is governed by a Le´vy walk have a larger probability of moving in a
given direction for a larger number of time-steps than a cell undergoing Brownian
motion, Fig.2b.
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2.3 Movement of activated immune cells
Once activated (see the following subsection), both types of immune cell alter their
movement from the Le´vy walk mechanism to a more spatially restricted mechanism
of Brownian motion. Therefore, activated cells will have equal probability, at each
time-step, to move to one of the eight neighbouring grid-sites, Fig.2c. If the desired
grid-site is occupied or outside the domain the cell will not move to the new site.
As we are considering an in vitro system, we assume that there will be no
influx or escape of immune cells into or from the domain, respectively. Using
reflective boundary conditions we ensure that cells cannot leave the domain. On
first approximation, we assume the total numbers of DCs and CTLs to remain
constant over time, that is, we omit the effects of proliferation and natural decay
of both CTLs and DCs.
2.4 Activation of immune cells
Inactive DCs can become activated by contact with the cancer cells. In the model,
we assume that when DCs are at a neighbouring grid-site to a cancer cell, the two
cells can interact and this can result in activation of the DCs at rate DAct, Fig.1b.
Inactive CTLs can become activated via interactions with activated DCs. If
activated DCs and inactive CTLs are at neighbouring grid-sites they can interact
and this may result in the activation of the CTLs with rate CAct, Fig.1c. Once a
DC has activated a CTL it can go on to activate other cells as we do not consider
any deactivation or exhaustion processes.
2.5 Destruction of tumour cells
Activated CTLs can interact with tumour cells if they are at neighbouring grid-
sites. The cancer cell can be removed upon interaction with a CTL at rate µ,
Fig.1d. Once a CTL has interacted with a cancer cell it can continue to seek out
and remove other cancer cells, since deactivation and exhaustion processes are not
considered here.
3 Simulation results
3.1 Model parametrisation and numerical set up
The mathematical model is parametrised using parameter values obtained from
published biological data wherever possible. The full list of parameters and related
references can be found in Table 2 in the Appendix.
To fix the size of the grid spacing, we consider the average diameters of all
three cell types, where melanoma cells are chosen as the cancer cells (see Table 1).
To reduce biological complexity to its essence, we assume each grid-site to be 10
µm apart in both the x and y direction. Therefore we set
∆x = 10 µm and ∆y = 10 µm. (2)
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Table 1 Average diameter of cell types considered
Cell Type Average Diameter Reference
Cytotoxic T lymphocyte 9-16 µm (Rozenberg, 2011)
Dendritic cell ∼ 7µm (Goya et al, 2008)
Melanoma cell ∼ 12.5 µm (Christophe et al, 2015)
Using 100 grid points in both the x and y directions, the 2D spatial domain is
therefore of size 1 mm2, representing a 1 mm2 in vitro sample.
To determine the time-step length ∆t we consider the speed of the immune
cells. The average speed of both inactive and activated CTLs has been found to
be approximately 10± 5µm min−1 (Boissonnas et al, 2007). Using an average cell
speed of 10µm min−1 for both immune cell types we choose
∆t = 1 min (3)
and so we let cells move one grid-step per time-step.
3.1.1 Proliferation of tumour cells
The proliferation rate of the cancer cells λ was taken from (Christophe et al,
2015), where the authors calculated the estimated proliferation rate of a cancer
cell using the average duplication time of melanoma cells. In particular, we choose
the proliferation rate of our cancer cells to be
λ = 0.001 min−1. (4)
At the beginning of simulations, the tumour mass is set up as a tightly packed
circle of cancer cells. Therefore, only cancer cells on the periphery of the circle
(circumference) will be eligible and able to proliferate.
3.1.2 Movement of inactive immune cells
As described previously, inactive cells will move using a Le´vy walk mechanism
taking their step length from the Le´vy distribution given by Eq.(1). Harris et al
(2012) studied the movement of CTLs in response to the pathogen Toxoplasma
gondii in the brain of infected mice. Using cell imaging, the movement of the CTLs
was tracked and matched to a Le´vy walk where the step length was taken from a
Le´vy distribution with exponent
α = 1.15. (5)
3.1.3 Activation of immune cells
Dendritic cells can collect tumour antigens from the surface of tumour cells to
become activated antigen presenting cells. Bianca et al (2012) found that the
activation rate of DCs by a tumour cell was
DAct = 0.07 cells min
−1. (6)
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The activated DCs can then present the tumour antigen to the CTLs, acti-
vating them to seek out and destroy cells displaying the tumour antigen. From
(Engelhardt et al, 2012) it can be calculated that it takes on average around 562
secs for a DC to activate a CTL through antigen presentation. This corresponds
to an activation rate
CAct ≈ 0.12 cells min−1. (7)
3.1.4 Movement of activated immune cells
As described previously, activated immune cells will move using Brownian motion.
At each time-step, these cells have an equal probability of moving to each of the
neighbouring grid-sites, if they are unoccupied.
3.1.5 Destruction of tumour cells
Activated CTLs can interact and initiate apoptosis in cells that display the tumour
antigen. Upon interaction with cancer cells, CTLs can initiate apoptosis in the
cancer cell at rate µ. Through studies using melanoma cells, Christophe et al
(2015) found this rate to be
µ = 0.038 cells min−1. (8)
3.2 Comparison with biological data of single CTL tracking
To confirm that using a Le´vy walk and a change to Brownian motion upon acti-
vation is an appropriate strategy for modelling immune cell motion, we attempted
to replicate qualitatively the biological data of Boissonnas et al (2007). The ex-
perimental data considered CTL motion over time in the presence or absence of a
tumour antigen. The data indicated that if the antigen is present the CTLs cover a
more restricted area, whereas in the absence of the antigen CTLs move in a search
type pattern exploring a wider portion of space over the same time interval. To
reproduce in silico the experimental setting used in (Boissonnas et al, 2007), we
considered 50 cells with their starting positions aligned and tracked each individ-
ual cell’s trajectory over time in the case where cells movement was modelled by
either Brownian motion, Fig.3c, or a Le´vy walk, Fig.3d. The boundaries of the
grid were reduced to match the biological results. Simulations were run over a
time period chosen to be consistent with the time frame of the experimental data,
??? Online Resources 1-2 ???. Apart from cell motion no other mechanisms were
included in this reduced version of the model. Our computational results are in
good qualitative agreement with the experimental results obtained in the presence
of a tumour antigen (compare the results in Fig.3c with the results in Fig.3a) and
in the absence of the antigen (compare the results in Fig.3d with the results in
Fig.3b).
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Fig. 3 Comparison with biological data of single CTL tracking. (a-b) Figures from
(Boissonnas et al, 2007) displaying overlay of 50 CTL tracks with aligned starting positions.
(a) CTL motion in the presence of a tumour antigen. (b) CTL movement when there is no
tumour antigen. (c-d) Computational results from our model showing overlay of 50 CTL tracks
with aligned starting positions. (c) CTLs moving via Brownian motion. (d) CTLs moving via
a Le´vy walk
Fig.2B: Image 1, Image 3, used with permission, from (Boissonnas et al, 2007)
c© 2007 A Boissonnas et al. Journal of Experimental Medicine. 204(2):345-356. doi: 10.1084/jem.20061890
3.3 Increasing the number of DCs can cause overcrowding and lead to longer
tumour removal times
Adoptive cell transfer aims to increase the number of activated CTLs which are
in the tumour microenvironment. Dendritic cell therapies have a similar approach
increasing the number of activated DCs in order to promote the activation of
CTLs. Bearing in mind these ideas, we can test the effect of varying the number
of immune cells present in the system using our IBM. Simulations were run over
a 72 hr period, in line with the experiments of Christophe et al (2015), or until
all of the tumour cells were removed from the system. All parameters remained
at set values from Table 2 except for the total number of CTLs, NC , and/or the
total number of DCs, ND, which were varied. Simulations were run with a range
of 40 different values of NC , ND or both NC and ND, where total immune cell
numbers ranged from 60 to 2400 cells. Heat maps were created to show the time
evolution of the total tumour cell number for different immune cell numbers, left
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panels of Fig.4. Selected values of 60, 420, 1200 and 2400 immune cells were chosen
to give a sample of the dynamics observed in each case. The time evolution of the
total tumour cell number was plotted for each of these cases, right panels of Fig.4.
Increasing the number of CTLs leads to a decrease in the time taken to remove the
tumour, top panels of Fig.4. However for larger cell numbers, i.e. 1200 and 2400
CTLs, there is little difference in tumour removal time. Generally, increasing the
DC number results into very little change in tumour removal time, middle panels
of Fig.4. When considering the sample dynamics for this case, the cases with 1200
and 2400 DCs are associated with longer tumour removal times than the case with
420 DCs. Moreover, the largest case considered, i.e. 2400 DCs, leads to a longer
tumour removal time than the smallest case considered, i.e. 60 DCs. Increasing
both NC and ND causes an descrease in tumour removal time, bottom panels of
Fig.4. As shown in Fig.9, similar dynamics are observed in the situation where the
tumour was initially larger containing 1200 tumour cells instead of 400 tumour
cells.
When carrying out simulations in the cases of increased immune cell numbers,
we observe larger numbers of CTLs or DCs surrounding the tumour, which ap-
pear to cause overcrowding and limit the access of the activated CTLs. We can
investigate this further by tracking the time evolution of the average distance of
CTLs from the centre of the tumour. In the case where CTLs are varied only with
either 1200 or 2400 cells we observe that in the latter case CTLs cannot get as
close to the tumour centre, Fig.5a and Online Resources 3-4. When increasing the
DC number only from 1200 to 2400 cells we see that CTLs are on average fur-
ther away from the tumour centre and DCs appear to cause overcrowding, which
pushes activated CTLs away from the tumour, Fig.5b and Online Resources 5-6.
When both CTLs and DCs are increased from 1200 cells to 2400 cells, we again
observe that the CTLs cannot get as close to the tumour centre in the latter case,
Fig.5c and Online Resources 7-8.
3.4 The ratio between the killing rate of tumour cells by CTLs and the tumour
cell proliferation rate is a crucial parameter in tumour removal
The rate at which a CTL can kill tumour cells has been previously shown to
be a key parameter in tumour removal (Matzavinos et al, 2004). Therefore, we
examine the effect of varying the rate at which a CTL can kill tumour cells, µ,
and we consider varying the tumour cell proliferation rate, λ. IBM simulations
were again run over a 72 hr period or until all of the tumour cells were removed
from the system. All parameters remained at set values from Table 2 except for µ
and λ. Simulations were run with a range of 40 values of µ, λ or both parameters.
The values of these parameters were scaled ranging from a half to twenty times
the original parameter values given in Table 2. Heat maps were created to show
the evolution of the total tumour cell number over time with varying values of µ
and/or λ, left panels of Fig.6. Selected values of a half, one, ten and twenty times
the original parameter values were chosen to give a sample of the dynamics in each
case, right panels of Fig.6. Increasing µ leads to an decrease in tumour removal
time, top panels of Fig.6. However, there is little difference in resulting dynamics
when multiplying our original value of µ by ten or twenty. Increasing λ leads to an
increase in the tumour removal time, and larger values lead to a larger number of
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Fig. 4 Increasing the number of DCs can lead to longer tumour removal times.
Heat maps showing the time evolution of the number of tumour cells for 40 different numbers of
immune cells (left panels) and selected samples of the time evolution of the number of tumour
cells for 4 different numbers of immune cells (right panels). In all cases under consideration,
at the beginning of simulations the tumour contained 400 cells. Top panels: Increasing the
CTL number NC we observe a general decrease in tumour removal time. Middle panels:
Increasing the DC number ND above a certain threshold leads to longer tumour removal time.
Bottom panels: Increasing both NC and ND causes a decrease in tumour removal time
tumour cells remaining after 72 hrs, middle panels of Fig.6. By increasing both λ
and µ we observe a general decrease in tumour removal time, slightly slower than
the cases where only µ is altered, bottom panels of Fig.6. As shown in Fig.10,
similar dynamics are observed in the case of an initially smaller tumour made up
of 400 cells and an initially larger tumour made up of 1200 cells.
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Fig. 5 Increasing the number of DCs can cause overcrowding. Samples of the time
evolution of the average distance of the CTLs from the centre of the tumour for different
numbers of CTLs, NC , and DCs, ND. The simulations are run and the average distance of the
CTLs from the tumour centre is calculated until all tumour cells are removed from the system.
(a) Increasing the number of CTLs only from 1200 cells (red line) to 2400 cells (blue line)
the CTLs do not get as close to the tumour centre; this limits the CTLs’ ability to remove
the tumour cells. (b) Increasing the number of DCs only from 1200 cells (red line) to 2400
cells (blue line) the CTLs do not get as close to the tumour centre and DCs appear to cause
overcrowding, which pushes activated CTLs away from the tumour (see also Online Resources
5-6). (c) Increasing both the number of CTLs and DCs from 1200 cells (red line) to 2400
cells (blue line) we observe that, on average, the CTLs are not as close to the tumour centre,
limiting their ability to remove the tumour cells.
3.5 Increasing the activation rates of DCs and CTLs has little effect on tumour
removal
Antigen presentation has been shown to be important in tumour removal (Bois-
sonnas et al, 2007). Hence, we investigate whether altering the rate at which DCs
become activated by the tumour antigen, DAct, and the rate at which CTLs are
activated by DCs, CAct, has an effect on tumour removal time. IBM simulations
were again run over a 72 hr period or until all of the tumour cells were removed
from the system. All parameters remained at set values from Table 2 except for
DAct and CAct. We consider two tumour situations: a smaller tumour made up
of 400 cells at the beginning of simulations, Fig.7, and a larger tumour made up
of 1200 tumour cells at the beginning of simulations, Fig.8. Simulations were run
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Fig. 6 The ratio between the killing rate of tumour cells by CTLs and the tumour
cell proliferation rate is a crucial parameter in tumour removal. Heat maps showing
the evolution of the number of tumour cells over time for 40 different values of the rate at
which CTLs kill tumour cells, µ, and/or the tumour proliferation rate, λ (left panels). Sample
time evolutions of the tumour cell number for 4 values of µ and/or λ (right panels). In all
cases under consideration, at the beginning of simulations the tumour contained 400 cells.
Top panels: Increasing µ we observe a decrease in tumour removal time, with little difference
between larger values. Middle panels: Increasing λ results in an increase in tumour removal
time and eventually a larger number of tumour cells remaining. Bottom panels: Varying
both λ and µ at equal ratios results in a decrease in tumour removal time for increasing values
of µ and λ, although (in general) tumour removal is slower than in the case where only µ is
varied
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with a range of 40 values of DAct and/or CAct where both rates were scaled rang-
ing from a half to twenty times the original parameter values found in Table 2.
Heat maps were created to show the total number of tumour cells over time for
varying values of DAct and/or CAct, left panels of Fig.7 and left panels of Fig.8.
Selected values of a half, one, ten and twenty times the original parameter values
were chosen to give a sample of the dynamics in each case, right panels of Fig.7
and right panels of Fig.8. In both the larger and smaller tumour situations, alter-
ing either DAct and/or CAct has no clear effect on tumour removal time, which
can be seen in the fluctuating results displayed by the heat maps. However, for
the case of a larger tumour, when consider the sample dynamics we observe that
larger immune activation rates can lead to slower tumour removal compared to
lower activation rates, right panels of Fig.8. This was not observed in the case of
a smaller tumour, right panels of Fig.7.
4 Discussion and conclusions
In this paper we have developed an individual-based spatial model of tumour-
immune competition focussing on cell-cell interactions between cancer cells, den-
dritic cells and cytotoxic T lymphocytes. The model explicitly takes into account
the difference in movement between inactive and activated immune cells. Our
simulation results demonstrate that the strategies we adopted to modelling im-
mune cell motion make it possible to qualitatively reproduce trajectories of CTLs
observed in experimental data (Boissonnas et al, 2007). In particular, Brownian
motion captures the movement of CTLs in the presence of a tumour antigen, whilst
a Le´vy walk provides a good representation of CTLs’ motion when the antigen is
not present.
Our theoretical work recapitulates previous experimental results showing that
increasing CTL numbers, to an extent, can have a beneficial effect on the immune
response to cancer (Spranger, 2016), whereas higher number of DCs can be detri-
mental to the anti-cancer immune action (Sato et al, 2004). In fact, we have shown
that, for a number of DCs given, increasing the number of CTLs leads to a faster
tumour removal time. On the other hand, for a given number of CTLs, sufficiently
larger numbers of DCs can bring about slower tumour removal than lower num-
bers. In agreement with the experimental results presented in (Li et al, 2010; Ye
et al, 2011) – where the authors showed that cellular overcrowding can hamper
immune action – our computational results indicate that higher numbers of DCs
can lead to overcrowding and prevent activated CTLs from reaching the tumour,
which results in reduced success of tumour removal. This could explain instances
of unsuccessful dendritic cell therapy (Ahmed et al, 2014; Butterfield, 2013; Garg
et al, 2017; Lim et al, 2007) and suggests that increasing CTL numbers may be a
better objective for immunotherapy rather than increasing DC numbers.
We have shown that the tumour cell proliferation rate (i.e. the parameter λ)
has a pronounced effect on tumour-immune competition. In fact, for a given value
of the rate at which CTLs can kill tumour cells (i.e. the parameter µ), larger
values of λ result in longer tumour removal times, eventually leading to situations
of uncontrolled tumour growth. However, if the value of the parameter µ is also
increased, in agreement with previous theoretical works (d’Onofrio and Ciancio,
2011; Frascoli et al, 2014; Matzavinos et al, 2004), our model predicts that tumour
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Fig. 7 Increasing the activation rates of DCs and CTLs has little effect on tumour
removal (400 tumour cells initially). Heat maps showing the evolution of the number of
tumour cells over time for 40 different values of the activation rate of the dendritic cells,
DAct, and the activation rate of the cytotoxic T lymphocytes, CAct (left panels). Sample
time evolutions of the tumour cell number for 4 selected activation rate values (right panels).
Top panels: Varying DAct does not have a great effect on tumour removal time as all values
give similar results. Middle panels: Varying CAct we observe similar results for each value.
However, larger values (twenty times the original value) result in slower tumour removal than
smaller values (half of the original value). Bottom panels: Varying both DAct and CAct we
obtain similar results for each value, with a general slight decrease in tumour removal time
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Fig. 8 Increasing the activation rates of DCs and CTLs has little effect on tumour
removal (1200 tumour cells initially). Heat maps showing the evolution of the number
of tumour cells over time for 40 different values of the activation rate of the dendritic cells,
DAct, and the activation rate of the cytotoxic T lymphocytes, CAct (left panels). Sample time
evolutions of the tumour cell number for 4 selected activation rate values (right panels). Top
panels: Varying DAct does not have a great effect on tumour removal time and for all values
we obtain similar results. However, larger values (twenty times the original value) result into
slower tumour removal than smaller values in the sample dynamics. Middle panels: Varying
CAct we observe similar results for each value. However, larger values (twenty times the original
value) result in slower tumour removal than smaller activation rates in the sample dynamics.
Bottom panels: Varying both DAct and CAct we observe that larger values (twenty times
the original value) correspond to slower tumour removal than smaller values
Modelling the immune response to cancer 17
eradication can be reestablished. Such results illustrate how the ratio µ/λ is a
crucial determinant of the outcome of anti-tumour immune action.
The outcomes of our model demonstrate that, in general, increasing the activa-
tion rates of CTLs and DCs (i.e. the parameters CAct and DAct, respectively) has
very little effect on removal of the tumour. Taken together, our results testify to
the idea that choosing the activation rates of CTLs and DCs as designated targets
in adoptive cell therapy, or other forms of immunotherapy, may not enhance the
efficacy of the immune response against solid tumours.
We conclude with an outlook on possible extensions of the present work. In our
model, immune cell proliferation and decay are not considered for simplicity. It
may be interesting to see if there is a change in dynamics upon inclusion of these
processes. Exhaustion and deactivation of the immune cells are also not considered
due to a lack of relevant data. However, preliminary simulations where DCs could
only activate limited numbers of cells gave similar results to the case where there
was no restriction on the number of CTLs a DC could activate. Similarly, when
CTLs could only kill a limited number of tumour cells, the results obtained were
similar to those of the case where there wass no restriction on the number of tumour
cells a CTL could kill. This suggests that the general conclusions of our work would
remain intact even in the presence of immune cell exhaustion or deactivation.
Tumour antigens can be either tumour specific antigens (TSAs), tumour asso-
ciated antigens (TAAs) or cancer/testis antigens (CTAs). TSAs are proteins that
only tumour cells produce, that is, no normal cells will produce them. TAAs are
most common and are produced by tumour cells, but also by some normal cells at a
low level of expression. This could impact the immune response to cancer as CTLs
may identify non-cancer cells as harmful due to the presence of TAAs, potentially
leading to autoimmunity. CTAs are specific to either tumour cells or reproductive
cells, but are unlikely to be found elsewhere (Yarchoan et al, 2017). The presence
of different types of antigens, or the ability of the tumour to mutate producing
different types of antigen, could be studied by extending the model. In the anti-
gen presentation process, major histocompatibility complex (MHC) molecules on
the surface of the dendritic cell bind to the antigens that are within the DC and
transport them to the external cell surface. Some tumours have been shown to
down-regulate MHC molecules preventing this process from occurring. In turn,
this blocks the activation of CTLs (Garrido et al, 2010). Our model could be fur-
ther developed to incorporate such an immunoevasion process. Tumour cells can
also directly attack the lymphocytes. Normally Fas ligand (FasL) from the lym-
phocyte binds to the Fas receptor on the tumour cell surface, they aggregate to
form a Fas associated death domain which activates a caspase cascade resulting in
apoptosis of the tumour cell (Hersey and Zhang, 2001). However, tumour cells can
also produce FasL and activate apoptosis of the CTLs through their Fas receptors
(Stewart and Abrams, 2008). This is a further level of complexity which could be
incorporated into our model.
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5 Appendix
Table 2 Values of parameters used in the model
Symbol Description Value/ Units References
∆t time-step of simulations 1 min (Boissonnas et al, 2007)
∆x(y) grid spacing in the x ( y) direction 10 µm Calculated
NT total number of tumour cells initial values: 400 or 1200 cells (Christophe et al, 2015)
NC total number of CTLs 400 cells (Christophe et al, 2015)
ND total number of DCs 400 cells Estimated
µ rate at which a CTL kills a tumour cell 0.03 cells−1 min−1 (Christophe et al, 2015)
λ tumour cell proliferation rate 0.001 min−1 (Christophe et al, 2015)
DAct DC activation rate 0.07 cells
−1 min−1 (Bianca et al, 2012)
CAct CTL activation rate ≈ 0.12 cells−1 min−1 (Engelhardt et al, 2012)
α Le´vy walk exponent 1.15 (Harris et al, 2012)
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Fig. 9 Increasing the number of DCs can lead to longer tumour removal times.
Heat maps showing the time evolution of the number of tumour cells for 40 different numbers of
immune cells (left panels) and selected samples of the time evolution of the number of tumour
cells for 4 different numbers of immune cells (right panels). In all cases under consideration,
at the beginning of simulations the tumour contained 1200 cells. Top panels: Increasing the
CTL number NC we observe a general decrease in tumour removal time. Middle panels:
Increasing the DC number ND above a certain threshold leads to longer tumour removal time.
Bottom panels: Increasing both NC and ND causes a decrease in tumour removal time
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Fig. 10 The ratio between the killing rate of tumour cells by CTLs and the tumour
cell proliferation rate is a crucial parameter in tumour removal. Heat maps showing
the evolution of the total number of tumour cells over time for 40 different values of the rate
at which CTLs kill tumour cells, µ, and/or the tumour cell proliferation rate, λ (left panels).
Sample time evolutions of the tumour cell number for 4 values of µ and/or λ (right panels). In
all cases under consideration, at the beginning of simulations the tumour contained 1200 cells.
Top panels: Varying µ we observe a decrease in tumour removal time with increasing values
of µ, with little difference between the larger values. Middle panels: Varying λ results in an
increase in tumour removal time with increasing λ and eventually a larger number of tumour
cells remaining. Bottom panels: Varying both λ and µ at equal ratios results in a decrease
in tumour removal time for increasing values of µ and λ, although (in general) is slower than
the case where only µ is altered
